Establishing a living biobank of patient-derived organoids of intraductal papillary mucinous neoplasms of the pancreas

• Published in: Laboratory investigation Vol. 101; no. 2; pp. 204 - 217
• Main Authors: Beato, Francisca, Reverón, Dayana, Dezsi, Kaleena B., Ortiz, Antonio, Johnson, Joseph O., Chen, Dung-Tsa, Ali, Karla, Yoder, Sean J., Jeong, Daniel, Malafa, Mokenge, Hodul, Pamela, Jiang, Kun, Centeno, Barbara A., Abdalah, Mahmoud A., Balasi, Jodi A., Tassielli, Alexandra F., Sarcar, Bhaswati, Teer, Jamie K., DeNicola, Gina M., Permuth, Jennifer B., Fleming, Jason B.
• Format: Journal Article
• Language: English
• Published: New York Elsevier Inc 01-02-2021; Nature Publishing Group US; Nature Publishing Group
• Subjects: 13/106; 45/22; 45/23; 631/67/1504/1713; 692/699/1503; Aged; Aged, 80 and over; Algorithms; Biobanks; Biological Specimen Banks; Biomarkers; Cancer; Cell Culture Techniques; Cryopreservation; Cysts; Digital imaging; Dysplasia; Female; Genomics; Histocytochemistry; Hough transformation; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Laboratory Medicine; Male; Medicine; Medicine & Public Health; Middle Aged; Morphology; Neoplasia; Neoplasms; Organoids; Organoids - cytology; Organoids - pathology; Pancreas; Pancreas - cytology; Pancreas - pathology; Pancreatic cancer; Pancreatic Intraductal Neoplasms - pathology; Pathology; Target detection; Tissue Culture Techniques; Tissues; Tumors
• ISSN: 0023-6837; 1530-0307; 1530-0307
• DOI: 10.1038/s41374-020-00494-1

Pancreatic cancer (PaCa) is the third leading cause of cancer-related deaths in the United States. There is an unmet need to develop strategies to detect PaCa at an early, operable stage and prevent its progression. Intraductal papillary mucinous neoplasms (IPMNs) are cystic PaCa precursors that comprise nearly 50% of pancreatic cysts detected incidentally via cross-sectional imaging. Since IPMNs can progress from low- and moderate-grade dysplasia to high-grade dysplasia and invasion, the study of these lesions offers a prime opportunity to develop early detection and prevention strategies. Organoids are an ideal preclinical platform to study IPMNs, and the objective of the current investigation was to establish a living biobank of patient-derived organoids (PDO) from IPMNs. IPMN tumors and adjacent normal pancreatic tissues were successfully harvested from 15 patients with IPMNs undergoing pancreatic surgical resection at Moffitt Cancer Center & Research Institute (Tampa, FL) between May of 2017 and March of 2019. Organoid cultures were also generated from cryopreserved tissues. Organoid count and size were determined over time by both Image-Pro Premier 3D Version 9.1 digital platform and Matlab application of a Circular Hough Transform algorithm, and histologic and genomic characterization of a subset of the organoids was performed using immunohistochemistry and targeted sequencing, respectively. The success rates for organoid generation from IPMN tumor and adjacent normal pancreatic tissues were 81% and 87%, respectively. IPMN organoids derived from different epithelial subtypes showed different morphologies in vitro, and organoids recapitulated histologic and genomic characteristics of the parental IPMN tumor. In summary, this preclinical model has the potential to provide new opportunities to unveil mechanisms of IPMN progression to invasion and to shed insight into novel biomarkers for early detection and targets for chemoprevention.
The authors report the feasibility of generating, expanding, and enumerating viable patient-derived intraductal papillary mucinous neoplasm (IPMN) tumor and normal pancreatic organoids from fresh and cryopreserved resected tissue. Organoids were characterized histologically and genomically and recapitulated the morphological and mutational profiles of resected IPMNs, suggesting promise of organoids for translational efforts.